Progress in Cardiovascular Diseases
Volume 53, Issue 2 , Pages 149-156, September 2010

Managing Coronary Artery Disease in the Cancer Patient

  • Ronald J. Krone

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Ronald J. Krone, MD, Professor, Department of Medicine, Division of Cardiology, Washington University School of Medicine, 660 S Euclid, Box 8086, St. Louis, MO 63130.

Abstract 

The cancer patient with coronary disease presents particular challenges that directly impact on the management of coronary disease, both stable and acute. The frequent need for surgery in the cancer patient is an important consideration in avoiding a coronary artery stent or any percutaneous coronary intervention for management of chronic stable angina, which will delay surgery or pose of risk of stent thrombosis during surgery. Cancer surgery is considered low or intermediate cardiac risk so revascularization before surgery is needed only in exceptional circumstances. Medical treatment in most patients or coronary artery bypass graft in high risk situations may be preferable if the cancer is being actively treated. The likelihood of thrombocytopenia, either primary from bone marrow disease, or secondarily during chemotherapy causes concern about the need for continuous use of platelet suppressing agents, aspirin for all patients, or double antiplatelet therapy in all patients after receiving a coronary artery stent. Drug-eluting stents pose special problems and should be avoided. Even bare metal stents may have a higher long-term risk of stent thrombosis in the cancer patient. The increase in propensity for venous clotting, either as a result of the cancer itself, or especially with selected chemotherapeutic agents may be an issue after stenting and certainly early after coronary bypass surgery. Aggressive medical treatment to reduce risk factors, especially with statins is essential to stabilize the underlying coronary disease.

Abbreviations and Acronyms: ACC/AHA, American College of Cardiology/American Heart Association, ACS, acute coronary syndrome, BMS, bare metal stents, CABG, coronary artery bypass graft surgery, CAD, coronary artery disease, DAPT, dual antiplatelet therapy (aspirin and a thienopyridine), DES, drug-eluting stents, ESC, European Society of Cardiology, PCI, percutaneous coronary intervention, STEMI, ST-segment elevation myocardial infarction

Keywords: Coronary artery disease, Cancer patient, Management

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Statement of Conflict of Interest: see page 154.

PII: S0033-0620(10)00109-X

doi:10.1016/j.pcad.2010.06.004

Progress in Cardiovascular Diseases
Volume 53, Issue 2 , Pages 149-156, September 2010